Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
First Patient Dosed With BXCL501 in Phase 3 TRANQUILITY II Trial in Alzheimer Agitation
May 7th 2022In a prior phase 1b/2 study, BXCL501 demonstrated statistically significant reductions in agitation measures with both the 30- and 60-mcg doses as measured by multiple scales with no severe or serious adverse events.
National Institutes of Health Launches Phase 1 Trial to Study Epstein-Barr Virus Vaccine
May 6th 2022The early-stage clinical trial will include 40 healthy volunteers to evaluate the safety and immune response of an investigational EBV gp350-Ferritin nanoparticle vaccine with a saponin-based Matrix-M adjuvant.
Multiple Sclerosis Severity Associated With Latitude in Temperate Zones, Driven by UVB Exposure
May 6th 2022In latitudes lower than 40°, the underlying environmental determinants of MS severity reached saturation and a ceiling effect was observed, with no further systematic shift in the disease severity.
FDA Permits Marketing for Plaque-Detecting Diagnostic Test for Alzheimer Disease
May 4th 2022Cerebrospinal fluid samples tested in a large cohort of patients at least 50 years of age with either mild cognitive impairment or Alzheimer disease showed high correlations between the Lumipulse G ß-Amyloid Ratio and PET status.
Risdiplam Demonstrates 3-Year Safety, Improved Motor Function in Spinal Muscular Atrophy
May 3rd 2022Over the 36-month period of the FIREFISH study and its extension, treatment with risdiplam (Evrysdi; Genentech) resulted in decreased rate of adverse events, serious adverse events, and number of hospitalizations.
Simulation Model Suggests Lecanemab Slows Rate of Disease Progression in Early Alzheimer
April 29th 2022A best-case analysis indicated that, for amyloid-positive patients diagnosed with MCI due to AD or mild AD dementia, lecanemab plus standard of care provided an additional gain of 0.75 in quality-adjusted life years.
Multiple Sclerosis Disease Activity, Progression of Disability Different Based on Sex
April 28th 2022The difference in inflammatory disease activity between men and women faded after the age of 50 years, whereas the sex difference in the neurodegenerative component of MS became apparent after the age of 45 years and deepened with older age.
NeuroVoices: Mark Lew, MD, on Exploring Reflex Tears as a Biomarker for Parkinson Disease
April 27th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
Addition of Mechanical Thrombectomy Improves Odds of Good Outcome in Elderly Poststroke Patients
April 26th 2022Following respective improvements in odds of good and poor outcomes, investigators concluded that the addition of mechanical thrombectomy should be considered over best medical management practices alone.
Significant Change in Valproate Prescribing Patterns Identified Following 2016 EMA Recommendations
April 23rd 2022The proportion of women exposed to valproate between the first and last trimester of pregnancy decreased alongside an increase in the proportion of women exposed to therapeutic alternatives such as lamotrigine and levetiracetam.